King's College London

Research portal

Applications of amyloid, tau, and neuroinflammation PET imaging to Alzheimer's disease and mild cognitive impairment.

Research output: Contribution to journalReview article

Standard

Applications of amyloid, tau, and neuroinflammation PET imaging to Alzheimer's disease and mild cognitive impairment. / Chandra, Avinash; Valkimadi, Polytimi Eleni; Pagano, Gennaro; Cousins, Oliver John; Dervenoulas, Georgios; Politis, Marios.

In: Human Brain Mapping, Vol. 40, No. 18, 15.12.2019, p. 5424-5442.

Research output: Contribution to journalReview article

Harvard

Chandra, A, Valkimadi, PE, Pagano, G, Cousins, OJ, Dervenoulas, G & Politis, M 2019, 'Applications of amyloid, tau, and neuroinflammation PET imaging to Alzheimer's disease and mild cognitive impairment.', Human Brain Mapping, vol. 40, no. 18, pp. 5424-5442. https://doi.org/10.1002/hbm.24782

APA

Chandra, A., Valkimadi, P. E., Pagano, G., Cousins, O. J., Dervenoulas, G., & Politis, M. (2019). Applications of amyloid, tau, and neuroinflammation PET imaging to Alzheimer's disease and mild cognitive impairment. Human Brain Mapping, 40(18), 5424-5442. https://doi.org/10.1002/hbm.24782

Vancouver

Chandra A, Valkimadi PE, Pagano G, Cousins OJ, Dervenoulas G, Politis M. Applications of amyloid, tau, and neuroinflammation PET imaging to Alzheimer's disease and mild cognitive impairment. Human Brain Mapping. 2019 Dec 15;40(18):5424-5442. https://doi.org/10.1002/hbm.24782

Author

Chandra, Avinash ; Valkimadi, Polytimi Eleni ; Pagano, Gennaro ; Cousins, Oliver John ; Dervenoulas, Georgios ; Politis, Marios. / Applications of amyloid, tau, and neuroinflammation PET imaging to Alzheimer's disease and mild cognitive impairment. In: Human Brain Mapping. 2019 ; Vol. 40, No. 18. pp. 5424-5442.

Bibtex Download

@article{a46f5b81d2f64a7ab3a5b791b23aaae9,
title = "Applications of amyloid, tau, and neuroinflammation PET imaging to Alzheimer's disease and mild cognitive impairment.",
abstract = "Alzheimer's disease (AD) is a devastating and progressive neurodegenerative disease for which there is no cure. Mild cognitive impairment (MCI) is considered a prodromal stage of the disease. Molecular imaging with positron emission tomography (PET) allows for the in vivo visualisation and tracking of pathophysiological changes in AD and MCI. PET is a very promising methodology for differential diagnosis and novel targets of PET imaging might also serve as biomarkers for disease‐modifying therapeutic interventions. This review provides an overview of the current status and applications of in vivo molecular imaging of AD pathology, specifically amyloid, tau, and microglial activation. PET imaging studies were included and evaluated as potential biomarkers and for monitoring disease progression. Although the majority of radiotracers showed the ability to discriminate AD and MCI patients from healthy controls, they had various limitations that prevent the recommendation of a single technique or tracer as an optimal biomarker. Newer research examining amyloid, tau, and microglial PET imaging in combination suggest an alternative approach in studying the disease process.",
keywords = "Alzheimer's disease, PET, amyloid, mild cognitive impairment, neuroinflammation, neuropathology, tau",
author = "Avinash Chandra and Valkimadi, {Polytimi Eleni} and Gennaro Pagano and Cousins, {Oliver John} and Georgios Dervenoulas and Marios Politis",
year = "2019",
month = dec,
day = "15",
doi = "10.1002/hbm.24782",
language = "English",
volume = "40",
pages = "5424--5442",
journal = "Human Brain Mapping",
issn = "1065-9471",
publisher = "Wiley-Liss Inc.",
number = "18",

}

RIS (suitable for import to EndNote) Download

TY - JOUR

T1 - Applications of amyloid, tau, and neuroinflammation PET imaging to Alzheimer's disease and mild cognitive impairment.

AU - Chandra, Avinash

AU - Valkimadi, Polytimi Eleni

AU - Pagano, Gennaro

AU - Cousins, Oliver John

AU - Dervenoulas, Georgios

AU - Politis, Marios

PY - 2019/12/15

Y1 - 2019/12/15

N2 - Alzheimer's disease (AD) is a devastating and progressive neurodegenerative disease for which there is no cure. Mild cognitive impairment (MCI) is considered a prodromal stage of the disease. Molecular imaging with positron emission tomography (PET) allows for the in vivo visualisation and tracking of pathophysiological changes in AD and MCI. PET is a very promising methodology for differential diagnosis and novel targets of PET imaging might also serve as biomarkers for disease‐modifying therapeutic interventions. This review provides an overview of the current status and applications of in vivo molecular imaging of AD pathology, specifically amyloid, tau, and microglial activation. PET imaging studies were included and evaluated as potential biomarkers and for monitoring disease progression. Although the majority of radiotracers showed the ability to discriminate AD and MCI patients from healthy controls, they had various limitations that prevent the recommendation of a single technique or tracer as an optimal biomarker. Newer research examining amyloid, tau, and microglial PET imaging in combination suggest an alternative approach in studying the disease process.

AB - Alzheimer's disease (AD) is a devastating and progressive neurodegenerative disease for which there is no cure. Mild cognitive impairment (MCI) is considered a prodromal stage of the disease. Molecular imaging with positron emission tomography (PET) allows for the in vivo visualisation and tracking of pathophysiological changes in AD and MCI. PET is a very promising methodology for differential diagnosis and novel targets of PET imaging might also serve as biomarkers for disease‐modifying therapeutic interventions. This review provides an overview of the current status and applications of in vivo molecular imaging of AD pathology, specifically amyloid, tau, and microglial activation. PET imaging studies were included and evaluated as potential biomarkers and for monitoring disease progression. Although the majority of radiotracers showed the ability to discriminate AD and MCI patients from healthy controls, they had various limitations that prevent the recommendation of a single technique or tracer as an optimal biomarker. Newer research examining amyloid, tau, and microglial PET imaging in combination suggest an alternative approach in studying the disease process.

KW - Alzheimer's disease

KW - PET

KW - amyloid

KW - mild cognitive impairment

KW - neuroinflammation

KW - neuropathology

KW - tau

UR - http://www.scopus.com/inward/record.url?scp=85073786234&partnerID=8YFLogxK

U2 - 10.1002/hbm.24782

DO - 10.1002/hbm.24782

M3 - Review article

VL - 40

SP - 5424

EP - 5442

JO - Human Brain Mapping

JF - Human Brain Mapping

SN - 1065-9471

IS - 18

ER -

View graph of relations

© 2018 King's College London | Strand | London WC2R 2LS | England | United Kingdom | Tel +44 (0)20 7836 5454